BRIEF—Novartis buys rights to novel small molecule from Fujifilm

Radiopharmaceuticals specialist Fujifilm Toyama Chemical has sold development and commercialization rights to its novel small molecule compound, FF-10158, to Advanced Accelerator Applications (AAA), a Novartis company.

Novartis has picked up rights for oncology indications both in diagnostics and therapeutics, outside of Japan. Fujifilm will receive undisclosed upfront, milestone and royalty payments.

AAA is focused on radiopharmaceuticals for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) diagnostic imaging, mainly for clinical oncology, cardiology and neurology.